Efficacy and effectiveness of raloxifene for preventing or lowering the danger of subsequent vertebral and/or nonvertebral fractures by improving BMD and lowering bone turnover in postmenopausal Japanese women with osteoporosis or osteopenia. Other findings suggest that raloxifene is effectively tolerated and can increase quality of life. However, these findings must be regarded in light from the limitations on the publications along with the threat enefit profile of raloxifene.AcknowledgmentsThe authors thank Shuko Nojiri of Eli Lilly Japan K.K. for her contributions on earlier Virus Protease Inhibitor supplier versions of this overview. Medical writing assistance was supplied by Julie Monk, PhD and Serina Stretton, PhD, CMPP (Certified Healthcare Publication Specialist) of ProScribe Health-related Communications, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Superior Publication Practice (GPP2).DisclosureThe study was funded by Eli Lilly Japan K.K., the manufacturer of raloxifene and teriparatide. SF has received ALDH1 drug speaker honoraria and consulting fees from Eli Lilly Japan K.K., Asahi-Kasei, Astellas, Chugai, Daiichi-Sankyo, Eisai, Ono,submit your manuscript | dovepressClinical Interventions in Aging 2014:DovepressDovepressSystematic review of raloxifene in Japan 18. Mithal A, Ebeling P. The Asia-Pacific Regional Audit. Epidemiology, Expenses and Burden of Osteoporosis in 2013. Nyon, Switzerland: International Osteoporosis Foundation; 2013. Obtainable from: iofbonehealth.org/sites/default/files/media/PDFs/Regional 20 Audits/2013-Asia_Pacific_Audit_0_0.pdf. Accessed August five, 2014. 19. Committee of Japanese Recommendations for the Prevention and Remedy of Osteoporosis. Japanese Guidelines for the Prevention and Remedy of Osteoporosis. Tokyo: Life Science; 2011. 20. Harada A, Matsui Y, Mizuno M, Tokuda H, Niino N, Ohta T. Japanese orthopedists’ interests in prevention of fractures inside the elderly from falls. Osteoporos Int. 2004;15(7):560?66. 21. Iwamoto J, Sato Y, Takeda T, Matsumoto H. Efficacy of antiresorptive agents for preventing fractures in Japanese individuals with an enhanced fracture risk: assessment with the literature. Drugs Aging. 2012;29(three): 191?03. 22. Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 2005;28(8):721?30. 23. Kanis JA, Johnell O, Black DM, et al. Impact of raloxifene on the risk of new vertebral fracture in postmenopausal females with osteopenia or osteoporosis: a reanalysis with the Various Outcomes of Raloxifene Evaluation trial. Bone. 2003;33(3):293?00. 24. Takada J, Miki T, Imanishi Y, et al. Effects of raloxifene remedy on the structural geometry of your proximal femur in Japanese ladies with osteoporosis. J Bone Miner Metab. 2010;28(five):561?67. 25. Uusi-Rasi K, Beck TJ, Semanick LM, et al. Structural effects of raloxifene on the proximal femur: final results from the Many Outcomes of Raloxifene Evaluation Trial. Osteoporos Int. 2006;17(4): 575?86. 26. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int. 2010;21(four):655?66. 27. Boivin G, Lips P, Ott SM, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation towards the enhance of your degree of mineralization of bone in postmenopausal girls. J Clin Endocrinol Metab. 2003;88(9):4199?205. 28. Nakamura T, Liu JL, Morii H, et al. Effect of raloxifene on c.